In conclusion, the presence of a CHEK2 1100delC mutation has currently no impact on the choice of type of systemic treatment in respective MBC patients, neither for chemotherapy nor for endocrine therapy, and our findings do not explain the previously reported worse survival regarding CHEK2 1100delC BC. Here, CHEK2 is linked to breast cancer.